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Abstract
Background: As a chronic antigenic stressor human Cytomegalovirus (CMV) contributes substantially to age-related
alterations of the immune system. Even though monocytes have the greatest propensity for CMV-infection and
seem to be an important host for the virus during latency, fibroblasts are also discussed to be target cells of CMV
in vivo. However, little is known so far about general immunoregulatory properties of CMV in fibroblasts. We
therefore investigated the immunoregulatory effects of CMV-infection in human lung fibroblasts and the impact on
replicative senescence.
Findings: We observed that CMV-infection led to the induction of several immunoregulatory host cell genes
associated with the innate and adaptive immune system. These were genes of different function such as genes
regulating apoptosis, cytokines/chemokines and genes that are responsible for the detection of pathogens. Some
of the genes upregulated following CMV-infection are also upregulated during cellular senescence, indicating that
CMV causes an immunological phenotype in fibroblasts, which is partially reminiscent of replicative senescent cells.
Conclusion: In summary our results demonstrate that CMV not only affects the T cell pool but also induces
inflammatory processes in human fibroblasts.
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Introduction
Cytomegalovirus (CMV) is a ubiquitous beta-herpesvirus
with a worldwide prevalence of 60-100% in the adult
population [1]. Infection occurs early and leads to life-long
persistence in the host. CMV is one of the most immuno-
dominant antigens and stimulates immune responses of
unprecedented magnitude [2]. Several studies have shown
that latent infection with cytomegalovirus contributes to
age-related alterations of the immune system, particularly
of the T cell compartment as it drives the differentiation
of T cells and accelerates immunosenescence [3]. In the
human host CMV exhibits tropism among others for
monocytes/macrophages, fibroblasts and endothelial cells
[4-6]. Previous reports demonstrate that CMV induces
premature senescence in early passage human fibroblasts.
Similar to senescent cells, which have reached the limit of
their replicative capacity [7], CMV-infected fibroblasts
show intense senescence-associated ß-Galactosidase (SA-
ß-gal) activity and increased mRNA expression of the cell
cycle arrest gene p16 [8,9]. Replicatively senescent fibro-
blasts characteristically also produce increased levels of
inflammatory molecules [10]. They may thus contribute to
the development of subclinical age-related inflammatory
processes (’inflamm-aging’) [11] and are believed to sup-
port the development of age-related diseases [12]. It is an
interesting and to our knowledge not yet addressed ques-
tion, whether CMV-infection of human fibroblasts not
only triggers replicative senescence, but also induces the
inflammatory phenotype characteristic for this differentia-
tion stage. This may be a trigger for a dysbalance between
pro- and antiinflammatory mechanisms and accelerate
immunosenescence from early life onwards. Therefore the
aim of this study was to investigate the effect of CMV on
the expression of genes associated with innate and adap-
tive immune response in human fibroblasts and to analyze
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state which is equal to that of replicative senescent cells.
Results and discussion
Previous work with fibroblasts showed that cellular senes-
cence is associated with changes in gene expression, parti-
cularly of the cellular secretome (senescence-associated
secretory phenotype; SASP) [10,13,14]. In our study a
broad analysis of the mRNA expression of immunity-
related genes in human lung fibroblasts of different pas-
sages of cultivation was carried out using the RT
2 Profiler
PCR Array. We observed that 28 genes out of 84 investi-
gated genes were differentially expressed in early versus
late passage fibroblasts (see Table 1) supporting previous
results of senescence-associated changes in gene expres-
sion. These are genes of different functional groups, with
mainly genes for the detection of pathogens (e.g. TLR4),
cytokines (e.g. IL6) or the innate immune response (e.g.
PGLYRP3) being upregulated.
Previous studies showed that CMV induces premature
senescence of infected cells [8,9]. In order to elucidate
whether CMV also influences the immunological pheno-
type, the expression of a panel of genes in CMV-infected
fibroblasts using a RT
2 Profiler PCR Array was analyzed.
We could show that in vitro CMV-infection of early pas-
sage fibroblasts leads to the induction of 35 inflammatory
genes. 9 of these genes ( = 25.7%, see Figure 1) upregu-
lated following CMV-infection are genes that are also
upregulated during replicative senescence of human fibro-
blasts (Table 1 depicted in bold), indicating that CMV
causes an immunological phenotype in early passage fibro-
blasts which is to some extent equal to that of uninfected
replicative senescent cells. The probability that this simul-
taneous regulation of genes associated in senescence and
CMV-infection was just chance was below 10% and could
have been even lower if more genes and not only immu-
noregulatory ones had been investigated. Most similarities
were found in the regulation of genes coding for cytokines,
chemokines and their receptors with the upregulation of
IL6 being the most prominent example. In addition to the
nine senescence-related genes CMV-infection triggered
the upregulation of additional 26 immunoregulatory genes
in early passage fibroblasts (see Table 1). These were
mainly genes regulating apoptosis and the NFkB pathway.
The expression of all 84 investigated genes was measured
at four different time points (6, 24, 48 and 72 hours) after
CMV-infection. Kinetics of gene regulation were variable
for the individual genes and revealed three patterns of
gene expression as shown in Figure 2. In most cases genes
were maximally upregulated 24 hours post infection and
either returned to basal level after 48 hours (Figure 2A) or
showed a relatively stable activation (Figure 2B). Only few
genes showed a continuous upregulation with a maximum
at 72 hours post infection (Figure 2C) and none of the
regulated genes was maximally upregulated 6 or 48 hours
post infection. The maximally observed fold regulation of
the genes following CMV-infection is shown in Table 1.
Superarray data were validated and confirmed using qRT-
PCR for several exemplary genes (data not shown).
In summary these data show that CMV influences the
mRNA expression of immunity-related host cell genes and
thereby causes a modification of the cellular microenvir-
onment. Furthermore we demonstrate that beyond par-
tially imitating senescence-related inflammation CMV
induces a robust inflammatory response in fibroblasts,
which may contribute to age-related inflammation later in
life. We cannot exclude that infection with other viruses
might induce similar responses. However, CMV has parti-
cularly been linked with cellular senescence [8,9,15]. In
this context IL6 is of particular interest since previous stu-
dies showed that high IL6 expression in combination with
CMV-infection is associated with an increased risk of
frailty in elderly people [16]. In general, virus-induced
alterations in the cellular expression of cytokines such as
IL6 may be important for the activation of specific leuco-
cytes and their recruitment to the site of infection, thereby
playing a role in viral pathogenesis. However, inappropri-
ate production of immunostimulatory molecules leads to
the excessive activation of the immune system and thereby
to chronic inflammation. Since CMV causes life-long
chronic latency in different human cells, leading to chronic
antigenic stimulation and to increased production of
immunity-related genes, CMV contributes to inflamm-
aging and aggravates immunosenescence.
In order to demonstrate that the induction of immunity-
related genes following CMV-infection is also translated
on the protein level ELISA experiments were performed.
IL6 cytokine secretion was chosen as an example and was
measured in the supernatants of untreated and CMV-
infected fibroblasts over a culture period of five days. As
shown in Figure 3 mock-infected fibroblasts produced low
levels of IL6, which accumulate in the supernatant over
time. Upon CMV-infection high IL6 concentrations could
be observed starting at day 3 confirming the gene regula-
tion observed on transcriptional level.
In conclusion our results demonstrate that CMV not
only affects the T cell pool but also induces inflammatory
processes in human fibroblasts. Therefore early life infec-
tion with CMV and episodes of reactivation throughout
life might induce immunoregulatory changes supporting
inflammatory processes and disease later in life.
Materials and methods
Cells
Human diploid fetal lung fibroblasts (Mrc-5) were culti-
vated in DMEM (Gibco Invitrogen Corporation, Paisley,
Scotland) supplemented with 10% FCS (Sigma-Aldrich,
Vienna, Austria), 100 Units/mL penicillin, 100 μg/mL
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Page 2 of 6Table 1 Differently expressed genes in early versus replicative senescent and CMV-infected versus untreated human
lung fibroblasts
Gene
symbol
Gene name Fold regulation in
replicative senescent
fibroblasts (mean ± S.E.
M.)
Maximally observed fold regulation
(mean ± S.E.M.) following CMV-
infection
Apoptosis CASP1 Caspase 1 - 2.4 ± 1.3
CASP4 Caspase 4 - 2.3 ± 1.3
TGFB1 Transforming growth factor, beta 1 - 2.1 ± 0.9
TNFRSF1A Tumor necrosis factor receptor
superfamily, member 1A
- 2.4 ± 1.6
Complement
activation
C5 Complement component 5 - 2.3 ± 1.5
C8A Complement component 8, alpha
polypeptide
6.8 ± 0.8 -
CD55 CD55 molecule, accelerating factor for
complement
- 4.3 ± 0.9
Cytokines,
chemokines and
their receptors
CCL2 Chemokine (C-C motif) ligand 2 - 2.8 ± 1.8
CXCR4 Chemokine receptor 4 - 57.8 ± 1.5
IFNA1 Interferon, alpha 1 3.7 ± 0.3 -
IFNGR1 Interferon gamma receptor 1 2.0 ± 0.4 3.2 ± 1.6
IFNGR2 Interferon gamma receptor 2 - 2.2 ± 1.6
IL1A Interleukin 1, alpha 6.4 ± 0.2 6.4 ± 1.6
IL1B Interleukin 1, beta 4.1 ± 0.1 8.9 ± 1.7
IL1F5 Interleukin 1 family, member 5 3.2 ± 1.2 -
IL1F7 Interleukin 1 family, member 7 8.9 ± 0.8 -
IL6 Interleukin 6 (interferon, beta 2) 10.2 ± 0.04 8.1 ± 1.5
TNF Tumor necrosis factor 3.2 ± 0.4 -
Detection of
pathogens
TLR2 Toll-like receptor 2 - 6.1 ± 5.4
TLR3 Toll-like receptor 3 - 5.9 ± 3.9
TLR4 Toll-like receptor 4 3.8 ± 0.9 5.4 ± 4.7
TLR6 Toll-like receptor 6 3.0 ± 0.2 -
TOLLIP Toll interacting protein - 2.5 ± 1.3
Defense response CAMP Cathelicidin antimicrobial peptide 8.3 ± 0.6 -
FN1 Fibronectin 1 2.5 ± 0.2 -
IL1receptor pathway IL1R1 Interleukin 1 receptor, type I - 2.9 ± 1.2
IL1RL2 Interleukin 1 receptor-like 2 - 5.3 ± 2.5
IL1RAP Interleukin 1 receptor accessory protein - 2.4 ± 1.8
IKBKB Inhibitor of kappa light polypeptide
gene enhancer
2.8 ± 0.2 -
MAPK8 Mitogen activated protein kinase 8 - 2.5 ± 1.5
MAPK14 Mitogen activated protein kinase 14 - 2.5 ± 1.3
Inflammatory
response
ADORA2A Adenosine A2a receptor 12.2 ± 3.0 4.2 ± 4.2
CCR3 Chemokine (C-C motif) receptor 3 12.3 ± 0.8 -
CD14 CD14 molecule 29.1 ± 1.0 -
CYBB Cytochrome b-245, beta polypeptide 8.5 ± 0.5 -
IRAK1 Interleukin-1 receptor-associated kinase 1 - 3.2 ± 1.7
IRAK2 Interleukin-1 receptor-associated
kinase 2
2.4 ± 0.04 2.7 ± 1.5
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glutamine (Sigma-Aldrich) at 37°C and 5% CO2.F o rt h e
experiments early passage fibroblasts (#22 - #26), show-
ing an exponential growth behavior, and late passage
fibroblasts (#45 - #48), that had entered the state of
terminally growth arrest, were used. To evaluate the
state of senescence of the fibroblasts, activity of SA-ß-
galactosidase at pH 5.8 [17] and gene expression of p15,
p16 and p21 were measured. For gene expression analy-
sis early and late passage fibroblasts were used, whereas
CMV-infection was performed with early passage
fibroblasts.
Virus
Human cytomegalovirus (strain Town-eGFP) was propa-
gated in Mrc-5 cells. Infectious virus particles in the
virus stock were quantified by a standard plaque assay.
Briefly, 500 μL of varying virus dilutions were added to
confluent Mrc-5 cells in a 12-well plate. After two hours
of incubation (37°C, 5% CO2) virus suspension was
removed, cell monolayers were covered with 2 mL
DMEM containing 1% methylcellulose (Sigma-Aldrich)
and incubated for 10 days. Then plaques were counted
Table 1 Differently expressed genes in early versus replicative senescent and CMV-infected versus untreated human
lung fibroblasts (Continued)
NOS2A Nitric oxide synthase 2A (inducible) 4.7 ± 0.9 -
PTAFR Platelet-activating factor receptor 4.5 ± 1.4 -
Innate immune
response
DMBT1 Deleted in malignant brain tumors 1 8.9 ± 1.4 -
PGLYRP1 Peptidoglycan recognition protein 1 10.7 ± 1.8 -
PGLYRP3 Peptidoglycan recognition protein 3 12.0 ± 1.1 -
SFTPD Surfactant, pulmonary-associated protein
D
10.0 ± 1.1 -
NFkB pathway CHUK Conserved helix-loop-helix ubiquitous
kinase
- 2.1 ± 1.3
MyD88 Myeloid differentiation primary response
gene
- 3.9 ± 1.8
NFKB2 Nuclear factor of kappa light
polypeptide gene enhancer in B cells 2
(p49/p100)
- 3.2 ± 1.6
NFKBIA Nuclear factor of kappa light
polypeptide gene enhancer in B cells
inhibitor, alpha
- 2.0 ± 0.9
TRAF6 TNF receptor-associated factor 6 - 2.3 ± 1.5
Other group COLEC12 Collectin subfamily member 12 2.2 ± 0.2 -
HMOX1 Heme oxygenase 1 - 2.0 ± 1.0
IRF1 Interferon regulatory factor 1 - 3.4 ± 1.8
LY96 Lymphocyte antigen 96 - 2.6 ± 1.7
NLRC4 NLR family, CARD domain containing
4
2.3 ± 0.2 2.7 ± 1.6
TREM1 Triggering receptor expressed on
myeloid cells 1
4.1 ± 1.1 10.0 ± 2.8
The fold regulation data represent the mean ± S.E.M. of three independent experiments calculated for each examined group and time point.
senescence CMV
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Figure 1 BioVenn diagram showing the number of immunity-
related genes upregulated in replicative senescent and CMV-
infected fibroblasts. Shown is the number of genes differentially
expressed in late passage compared to early passage fibroblasts
(senescence) and the number of genes differentially expressed in
CMV-infected versus untreated fibroblasts (CMV). 9 genes are
regulated in both analyses. Depicted are genes that were
reproducibly regulated in three independent experiments.
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Page 4 of 6under a fluorescence microscope. The viral concentra-
tion is expressed as plaque-forming units per mL (pfu/
mL). All in vitro experiments with the virus were per-
formed with a multiplicity of infection (MOI) of 1.
CMV-infection of fibroblasts
For CMV-infection fibroblasts were seeded in 6-well
plates and maintained in supplemented DMEM until
they reached 100% confluency. Culture medium was
removed and replaced by virus-containing medium.
Untreated fibroblasts were used as a control (mock-
infected). Supernatants were collected over several days
as indicated and used for cytokine profiling by ELISA.
Additionally, cells were harvested for isolation of total
mRNA.
Total RNA-isolation and qRT-PCR
Total cellular RNA was extracted from fibroblasts
using the RNeasy Plus Mini Kit (Qiagen, Hilden, Ger-
many). 0.25-0.5 μg of total RNA was used for cDNA
synthesis, which was performed using the Reverse
Transcription system A3500 with Oligo (dT)-primers
(Promega, Madison, USA). cDNA sequences were
amplified by qRT-PCR using the ‘Light Cycler
® 480
System’ with the 2 × LightCycler 480 SYBR Green 480
master mix (Roche, Basel, Switzerland). Sequence-spe-
cific oligonucleotide primers were designed using Pri-
mer3 software [18] and synthesized by MWG Biotech
(Ebersberg, Germany).
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Figure 2 mRNA levels of IFNGR1, ADORA2A and IL6 over time
in CMV-infected fibroblasts. Human lung fibroblasts were in vitro
infected with CMV. Cells were harvested at the indicated time
points, total RNA was isolated and gene expression of (A) IFNg
receptor 1 (IFNGR1), (B) adenosine A2A receptor (ADORA2A) and (C)
Interleukin-6 (IL6) was analyzed using a RT
2 Profiler PCR Array. Gene
expression of CMV-infected fibroblasts was calculated in relation to
gene expression of mock-infected fibroblasts. IFNGR1 and ADORA2A
were maximally upregulated 24 hours post infection. While IFNGR1
expression returned to basal levels after 48 hours, ADORA2A was
relatively stable expressed over time. In contrast IL6 showed a
continuous upregulation of gene expression with a maximum at 72
hours following CMV-infection. The arithmetic mean ± S.E.M. were
calculated for each examined group and time point (three
independent experiments).
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Figure 3 IL6 protein levels in the supernatant of human
fibroblasts following in vitro infection with CMV. Human lung
fibroblasts were left untreated (mock) or infected with the CMV
strain Town-eGFP. IL6 protein secretion of mock- and CMV-infected
fibroblasts was analyzed by ELISA over a time period of 5 days. The
arithmetic mean ± S.E.M. were calculated for each examined group
and time point. Comparisons between two groups were analyzed
by Student’s t-test, using SPSS version 19.0 (SPSS Inc., Chicago,
Illinois, USA). p values below 0.05 were considered as statistically
significant. * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001.
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2 Profiler PCR Array
To determine the profile of genes associated with the
human innate and adaptive immune response (for a
complete list refer to http://www.sabiosciences.com/
rt_pcr_product/HTML/PAHS-052A.html) of untreated
and CMV-infected fibroblasts, a RT
2 Profiler PCR Array
(SA Biosciences™/Qiagen) was used. The obtained data
were analyzed using a Web-Based Data Analysis tool
(http://pcrdataanalysis.sabiosciences.com/pcr/arrayanaly-
sis.php).
Cytokine profiling
Supernatants of fibroblasts were analyzed in duplicates
for the presence of IL6 protein by a commercially avail-
able ELISA kit (MabTech, Hamburg, Germany).
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